dc.contributor | Vall d'Hebron Barcelona Hospital Campus |
dc.contributor.author | Garrido, Pilar |
dc.contributor.author | Paz-Ares, Luis |
dc.contributor.author | Majem Tarruella, Margarita |
dc.contributor.author | Morán, Teresa |
dc.contributor.author | Trigo, José Manuel |
dc.contributor.author | Bosch-Barrera, J |
dc.contributor.author | Felip Font, Enriqueta |
dc.date.accessioned | 2022-02-01T13:21:37Z |
dc.date.available | 2022-02-01T13:21:37Z |
dc.date.issued | 2021-09 |
dc.identifier.citation | Garrido P, Paz-Ares L, Majem M, Morán T, Trigo JM, Bosch-Barrera J, et al. LungBEAM: A prospective multicenter study to monitor stage IV NSCLC patients with EGFR mutations using BEAMing technology. Cancer Med. 2021 Sep;10(17):5878–88. |
dc.identifier.issn | 2045-7634 |
dc.identifier.uri | https://hdl.handle.net/11351/6948 |
dc.description | Mutacions de l'EGFR; Biòpsia líquida; Carcinoma de pulmó de cèl·lules no petites |
dc.description.sponsorship | This work was supported by Sysmex Inostics GmbH. The sponsor and the study coordinating investigators were involved in the study design and data interpretation. Writing and editorial assistance was funded by Sysmex Inostics GmbH. |
dc.language.iso | eng |
dc.publisher | Wiley |
dc.relation.ispartofseries | Cancer Medicine;10(17) |
dc.rights | Attribution 4.0 International |
dc.rights.uri | http://creativecommons.org/licenses/by/4.0/ |
dc.source | Scientia |
dc.subject | Pulmons - Càncer - Prognosi |
dc.subject | Pulmons - Càncer - Tractament |
dc.subject | ADN - Anàlisi |
dc.subject.mesh | Carcinoma, Non-Small-Cell Lung |
dc.subject.mesh | Neoplasms |
dc.subject.mesh | DNA Mutational Analysis |
dc.title | LungBEAM: A prospective multicenter study to monitor stage IV NSCLC patients with EGFR mutations using BEAMing technology |
dc.type | info:eu-repo/semantics/article |
dc.identifier.doi | 10.1002/cam4.4135 |
dc.subject.decs | carcinoma de pulmón de células no pequeñas |
dc.subject.decs | /diagnóstico |
dc.subject.decs | análisis de mutaciones del ADN |
dc.relation.publishversion | https://doi.org/10.1002/cam4.4135 |
dc.type.version | info:eu-repo/semantics/publishedVersion |
dc.audience | Professionals |
dc.contributor.organismes | Institut Català de la Salut |
dc.contributor.authoraffiliation | [Garrido P] Medical Oncology Department, IRYCIS Hospital Universitario Ramón y Cajal, Universidad Alcalá, Madrid, Spain. CIBERONC, Madrid, Spain. [Paz-Ares L] CIBERONC, Madrid, Spain. Medical Oncology Department, Hospital Universitario 12 de Octubre and i+12 Research Institute, Madrid, Spain. Lung Cancer Group, Clinical Research Program, Spanish National Cancer Research Center (CNIO), Madrid, Spain. Complutense University, Madrid, Spain. [Majem M] Medical Oncology Department, Hospital De La Santa Creu I Sant Pau, Barcelona, Spain. Spanish Lung Cancer Group (GECP), Barcelona, Spain. [Morán T] Spanish Lung Cancer Group (GECP), Barcelona, Spain. ICO Badalona, Hospital Germans Trias i Pujol, Barcelona, Spain. [Trigo JM] Medical Oncology Department, Hospital Universitario Virgen de la Victoria, Málaga, Spain. [Bosch-Barrera J] Medical Oncology, Catalan Institute of Oncology (ICO), Dr. Josep Trueta Hospital of Girona, Girona, Spain. [Felip E] Servei d’Oncologia Mèdica, Vall d’Hebron Hospital Universitari, Barcelona, Spain |
dc.identifier.pmid | 34296539 |
dc.identifier.wos | 000676107800001 |
dc.rights.accessrights | info:eu-repo/semantics/openAccess |